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Abstract 
Hepatitis C virus (HCV) replication is associated with 
the endoplasmic reticulum, where the virus can induce 
cellular stress. Oxidative cell damage plays an important 
role in HCV physiopathology. Oxidative stress is trig-
gered when the concentration of oxygen species in 
the extracellular or intracellular environment exceeds 
antioxidant defenses. Cells are protected and modulate 
oxidative stress through the interplay of intracellular 
antioxidant agents, mainly glutathione system (GSH) 
and thioredoxin; and antioxidant enzyme systems such 
as superoxide dismutase, catalase, GSH peroxidase, 
and heme oxygenase-1. Also, the use of natural and 
synthetic antioxidants (vitamin C and E, N-acetylcysteine, 
glycyrrhizin, polyenylphosphatidyl choline, mitoquinone, 
quercetin, S-adenosylmethionine and silymarin) has 
already shown promising results as co-adjuvants in 
HCV therapy. Despite all the available information, it is 
not known how different agents with antiviral activity 
can interfere with the modulation of the cell redox 
state induced by HCV and decrease viral replication. 
This review describes an evidence-based consensus on 
molecular mechanisms involved in HCV replication and 
their relationship with cell damage induced by oxidative 
stress generated by the virus itself and cell antiviral 
machinery. It also describes some molecules that 
modify the levels of oxidative stress in HCV-infected 
cells.
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Core tip: This review focuses on the available findings 
regarding the relationship between viral and cellular 
proteins and the resulting regulation of oxidative stress. 
To understand the liver damage induced by hepatitis C 
virus and its persistence is important to know how the 
cell regulatory systems involved in the production and 
elimination of reactive oxygen species (ROS) benefit the 
replication of the virus, as well as their participation in 
the cell defense mechanisms and immune perturbation 
following the infection. We must also consider the 
involvement of ROS in signaling pathways that induce 
viral replication and its implication in antiviral therapies.
Lozano-Sepulveda SA, Bryan-Marrugo OL, Cordova-Fletes 
C, Gutierrez-Ruiz MC, Rivas-Estilla AM. Oxidative stress 
modulation in hepatitis C virus infected cells. World J Hepatol 
2015; 7(29): 2880-2889  Available from: URL: http://www.
wjgnet.com/1948-5182/full/v7/i29/2880.htm  DOI: http://dx.doi.
org/10.4254/wjh.v7.i29.2880
INTRODUCTION 
The number of deaths as a result of liver cirrhosis 
and cancer rose by 50 million in the last two decades, 
according to the first-ever World Health Organization 
study on liver disease mortality. Liver cancer is largely 
a problem in developing countries accounting for 83% 
of the estimated 782000 new cases occurred in 2012. 
Liver cancer is the fifth most common type of cancer 
reported in men and the ninth in women. Liver cancer 
is the second leading cause of death by cancer around 
the world, and it is considered to be responsible for 
nearly 746000 deaths in 2012 (9.1% of the total). The 
prognosis for liver cancer patients is very poor (overall 
ratio of mortality to incidence of 0.95), and as such, 
the geographical patterns in incidence and mortality 
are frighteningly similar[1]. The highest hepatitis C virus 
(HCV) prevalence worldwide are reported in the Western 
Pacific, Southeast Asia, and Africa regions, with around 
120 million people infected who have limited access 
to the new anti-HCV drugs. It is important to mention 
that most of the people with HCV infection do not live 
in North America, Europe, or Japan (approximately 
3.2 million people in the United States are chronically 
infected with HCV), which are the primary market for 
current anti-HCV drugs. In addition, it is well known 
that low- and middle-income countries, like Egypt (22%) 
and China (3.2%), report the highest prevalence. 
Although HCV genotypes 1 and 3 are more prevalent 
in most countries regardless of economic status, the 
largest proportions of genotypes, 4 and 5 are in low-
income countries[2-4]. The total population infected with 
HCV in Latin America in 2010 was estimated at 7.8 
million, of which 4.6 million are infected with genotype 
1 (approximately 70% with subtypes 1a and 1b) and 
genotypes 2a, 2b, 2c and 3a which constitute 25% of 
the remaining genotypes, whereas the other genotypes 
4 to 7 are less common[5]. It is estimated that up to 3% 
of the global population (approximately 150-170 million 
persons) is infected with chronic hepatitis C. HCV has 
been demonstrated to be the leading cause of chronic 
liver disease[4], cirrhosis and hepatocellular carcinoma 
(HCC), and is the underlying cause of over 475000 
annual deaths, worldwide[6].
There is still no anti-HCV vaccine available and 
until recently, the only approved treatment, based on 
a combination of pegylated interferon (PEG-INF) and 
ribavirin (RBV), was partially effective in treated patients 
and also had considerable side effects in most of the 
patients[7]. Recently, after several years of research, 
new therapies that specifically block the virus have been 
developed. In 2011, the first anti-HCV specific drugs 
were approved for clinical use. Since then, a new era 
began for HCV infected patients with the founding of new 
direct acting agents (DAAs)[8,9]. However, the availability 
and accessibility of new protease inhibitors, telaprevir, 
boceprevir, simeprevir; and the recently approved RNA 
polymerase inhibitor sofosbuvir, depends on the region 
where patients are located and their access through 
government health programs, since the costs of DAAS 
are high. Increasing response rates are expected in the 
near future due to the development of numerous new 
DAAs and host-targeted drugs active against HCV[10-12]. 
There are constant efforts to identify new cheaper and 
effective antiviral molecules through other therapeutic 
approaches. Recent antioxidant compounds reports 
highlight their antiviral activity against HCV and post 
them as anti-HCV co-adjuvants that can improve the 
effectiveness of treatment as well as shorten the period 
and reduce the overall cost of the therapy.
HCV MOLECULAR BIOLOGY
HCV is a positive-strand RNA virus, classified into the 
Hepacivirus genus (Flaviviridae family), with a genome 
around 9600 nucleotides in length. The single strand 
genome carries a 50 and 30 nt length in non-coding 
region (NCR) flanking a single open-reading frame, 
encoding a single polyprotein of around 3009 aminoacid 
residues. Interestingly, this 50 NCR forms an internal 
ribosome entry site that leads the translation of the 
viral polyprotein, which in turn is cleaved by both viral 
and host proteases, in order to produce the structural 
(core, E1 and E2) and non-structural (NS2 to NS5B) 
viral proteins. There are numerous reports about the 
interaction between viral and cellular proteins to facilitate 
replication of the virus, however more information is 
needed to understand their role in the pathophysiology 
of the disease[13,14].
HCV AND OXIDATIVE STRESS
It is well known that most of the viral replication cycle 
takes place associated with the endoplasmic reticulum 
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(ER), which encourages cellular stress. This effect has 
been associated with a specific regulation of the virus 
replication cycle[15]. It is reported that viral proteins 
such as HCV-core, E1, and NS3 can modulate and 
inactivate mitochondrial respiratory chain enzymes and 
in turn unshackle blockade of the electrons, disruption 
of mitochondrial transmembrane potential, and electron 
leakage inducing an increase of intracellular reactive 
oxygen species (ROS) levels[16,17]. Together, all these 
molecular events impair mitochondrial and cellular signa-
ling pathways. 
The generation of oxygen species in several biological 
processes exceeds the capacity of antioxidant systems. 
A greater imbalance in the pro-oxidant and antioxidant 
ratio in benefit of the pro-oxidant can induces cellular 
damage[15,18].
Several reports demonstrate that expression of HCV 
proteins increase ROS levels due to activation of several 
pathways including the activation of mitogen-activated 
protein kinase (MAPK), ER response, Nuclear factor kB 
(NF-kB) and calcium signaling[19]. In the cytoplasm, 
the ER is actively involved in the induction of ROS, 
since excessive production of viral proteins induces the 
unfolded proteins response which is accompanied by 
calcium release. Then, the mitochondria absorbed the 
released calcium quickly, giving as a result an elevation 
of ROS. The constant production of ROS is a challenge 
that the cell has to overcome to survive. Normally, 
cells have sufficient capacity to balance the demand 
for antioxidant compounds and enzymatic antioxidant 
systems with the production of ROS[20], then modulating 
or blocking tissue damage. A biological condition that 
disrupts this balance, can induce accumulation of ROS 
and oxidative stress. Among the mechanisms involved 
in cell protection against oxidative stress damage we 
can found several intracellular antioxidant agents (gluta-
thione, S-adenosil-methionine and thioredoxin), and 
antioxidant enzymes (superoxide dismutase, catalase, 
GSH peroxidase and heme oxygenase-1)[21-23].
In fact, there are large amount of data demon-
strating that several intracellular signaling pathways are 
altered by HCV proteins in order to promote replication. 
The HCV can do accomplish this by finely regulating the 
oxido-reductive state of the host cell. MAPK and phos-
phoinositide-3 kinase (PI3K)/Akt signaling pathways 
are critical controllers of HCV replication and in turn, 
these pathways are modulated by phosphorylation 
cascades and oxidative stress. The first evidences that 
a virus could induce oxidative stress by increasing 
ROS levels, were published by Peterhans et al[24] in 
1979. They demonstrated that the infection of mouse 
splenocytes with Sendai virus induced an increase of 
chemiluminescence levels, which it meant that the 
luminol had been oxidized by ROS in the experimental 
setting. They demonstrated that virus inactivated 
with UV light are able to generate ROS too, whereas 
virus inactivated by heating could not generate ROS, 
suggesting that viral structure conformation are media-
ting this action[24].
It has been shown that oxidative damage has a major 
role in HCV-induced liver damage, via ROS accumulation, 
produced from HCV infected cells and infiltrating immune 
cells[25,26]. The high amount of either HCV-structural 
or non structural proteins induce oxidative stress and 
disrupt the antioxidant equilibrium into the cells. In 
addition, a direct interaction of the HCV-core protein 
with mitochondria is able to decrease the mitochondrial 
NADPH levels, reducing the activity of the electron 
transport complex Ⅰ and then increasing generation of 
ROS. It has been shown that HCV-core protein over-
expression diminished GSH levels and induced GSSG 
levels. In addition, an expected compensatory response 
increases the major enzymatic antioxidant elements 
such as GSH reductasa, catalase, MnSOD and heme 
oxygenase-1 (HO-1), in infected cells[27].
It is reported that expression of viral core protein 
induces the expression of p21-waf1, activates the NF-
kB, bind to p53 and induces oxidative stress markers 
(ROS and peroxidated lipids)[28-30]. There is a differential 
effect on the enzymatic antioxidant systems in response 
to the presence of different viral proteins. Abdalla et 
al[31] reported that HCV infection reduced in vivo hepatic 
expression of HO-1 and in vitro HCV-core protein 
expression causes a similar effect, but this effect is not 
detected in superoxide dismutase (SOD) and catalase 
enzymes. This group also studied the effect of HCV-core 
expression in regulation of GSH levels. They findings 
demonstrated that GSH levels were diminished upon 
HCV-core expression, but at the same time oxidized 
GSH (GSSG) levels were undetectable. This finding 
led them to evaluate if thioredoxin (Trx) was also 
regulated by HCV-core protein, and they found that 
in fact Trx was also oxidated. As expected there is a 
compensatory induction of anti-oxidant defenses in 
cells expressing viral proteins[31]. On the other hand, 
expression of non-structural protein 5A (NS5A) up-
regulates mitochondrial ROS levels because it induces 
the release of calcium from ER, binds to PI3K and 
triggers NF-kB signaling[19,32-34]. This event is followed 
by a translocation of NF-kB to the nucleus, where it 
binds to DNA and activates several gene promoters. In 
addition, activation of NF-kB signaling can be blocked by 
several antioxidants[35]. Figure 1 Possible interactions/
mechanisms of antioxidant agents with reported anti-
HCV effect. 
On the other hand, twenty years ago, Suematsu et 
al[36] showed that patients with hepatitis C had increased 
serum lipid peroxides, and further this increase was also 
confirmed by Higueras et al[37], but interestingly they 
reported that lipid peroxides levels were decreased in 
patients treated with alpha-interferon. Still, it has not 
been defined whether this effect was due to the decrease 
of viral replication and inflammation or a combination of 
induction of antioxidant enzymes by the alpha-interferon 
treatment[37]. Another important component in this viral 
redox imbalance is the transcription factor Nrf2, reported 
by Waris et al[33] in 2010. An independent study by 
Ivanov et al[38], on Huh7 cells reported that induction of 
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immune system. It is known that processing of HCV 
proteins are performed in the ER but HCV proteins 
accumulate at the space between the mitochondrial 
outer membrane and ER. It has been reported that HCV 
proteins can move from the ER synthesis site to the 
mitochondria, therefore, there is an interaction between 
HCV proteins with the mitochondrial machinery in hepatic 
and extra-hepatic sites. Impairment of mitochondria-
nuclear cross talk through involvement of PI3 kinases 
has been published by Bhargava et al[17], 2011.
ANTIOXIDANT THERAPY
It has been shown that HCV modifies antioxidant 
defense mechanisms yielding a cellular oxidative imba-
lance[29,31,41]. Several authors, including our research 
group, have demonstrated that HCV effectively modifies 
gene expression regulatory proteins of oxidative stress 
as SOD and catalase[26,31,33]. The limitations of interfering 
with such mechanisms in viral diseases are similar to 
those when interfering with oxidant generation. This 
is a result of the association between these pathways 
with the normal host physiology as well as with host 
pathology. It is clear that antioxidant therapy could be 
criticized because it involves a wide variety of drugs, 
rather than the magic one or two putatively specific 
ones used in modern pharmacotherapy. The most 
common antioxidant used in several clinical trials and 
in vitro experiments are described in Table 1. However, 
because the symptoms and pathology of viral diseases 
are ultimately the result of complex host reactions 
in addition to direct viral effects, there is a scientific 
basis for this strategy of viral disease therapy. Clearly, 
this does not obviate the need for further research to 
identify a drugs that may specifically interfere with viral 
replication[40,42,43]. The modulation of major signaling 
the Nrf2/ARE signaling pathway is triggered at least by 
five of the HCV viral proteins (core, E1, E2, NS4B, and 
NS5A). It is reported that virus can affect the cell redox 
equilibrium by inducing cellular pro-oxidants such as 
Fe2+/3+ ions, nitric oxide and by decreasing the synthesis 
of antioxidant enzyme systems. In addition, ROS could 
regulate virus replication modulating oxidative stress 
present in the infected cell in order to choose survivors 
viral mutants, by inducing mutations and also by 
activating transcription factors such as NF-kB that could 
participate in viral protein expression[39]. Based on the 
multiple oxidant and antioxidant activities performed in 
vivo and in vitro systems during viral infections, and the 
variable ability of antioxidants to cross cell membranes, 
the systematic use of antioxidants as antiviral therapies 
had been limited[40].
On the other hand, HCV is potentially lymphotropic, 
because it can invade and propagate in cells of the 
Antioxidant therapy alone or combined
VHC
Scavengers Antifibrotic and scavenger Different mechanisms IFN signaling sensibilization COX-2 and SOD-1 modulation
Vitamin E
Vitamin C
NAC
MitQ
α-tocopherol
L-glutathione
Glycyrrhizin
Zn
Silymarin compounds:
   Silibinin A
   Silibinin B
Quercetin
Gallic acid
SAM ASA
Figure 1  Possible interactions/mechanisms of antioxidant agents with reported anti-hepatitis C virus effect. SOD: Superoxide dismutase; SAM: 
S-adenosylmethionine; ASA: Acetylsalicylic acid; Zn: Zinc; IFN: Interferon.
Table 1  Most common antioxidant used in several clinical 
trials and in vitro  experiments
Antioxidant Dose range
Scavengers
   Vitamin E[47,48] 400-544 IU/d or 600 mg1
   Vitamin C[48] 500 mg-10 g 
   N-acetylcysteine[78] 600 mg or 1800 mg/d1 
   Mitoquine Q[65,66] 40 or 80 mg/d
   α-tocopherol[79] 600 mg, 500 mg/d, 800 IU/d 
   Glycyrrhizin[40,42,53,54] 500 mg, 120 mg 
Different mechanisms
   Silymarin (Silibinin A, Silibinin B, 
   etc.)[40,64,80-82]
250 mg or 5-20 mg/kg1
   S-adenosylmethionine[69] 1600 mg/d1
   Acetylsalicylic acid[73] 4 mmol/L (in vitro) 
   Gallic acid 300 mg/mL (in vitro)
1Combined treatment with interferon.
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pathways by high cell ROS levels are shown in Figure 2. 
VITAMINS C AND E
Vitamin C (ascorbic acid) is as an electron donor in 
enzymatic reactions and thus can block free radical 
chain reactions. Vitamins C, A, and E are the most 
important natural antioxidants associated with cell-
mediated immunity and toxic hepatitis[44]. Vitamin C 
defends cells from free radical damage by reducing 
radicals, scavenging lipid-peroxidation-derived radicals, 
or reducing tocopherol radicals to tocopherol[45]. In 
cells, vitamin E is the major lipid soluble chain-breaking 
antioxidant in mitochondria, microsomes, and lipo-
proteins[46]. von Herbay et al[47] reported that vitamin E 
decreases the hepatic aminotransferase levels in patients 
whit chronic HCV infection. Murakami et al[48] observed 
that antioxidant vitamins (E and C) supplemented 
during interferon alpha treatment inhibited the decrease 
in eicosapentaenoic acid of mononuclear cell. They 
also stated that it might be possible to enhance the 
efficacy of combination therapy of interferon alfa-2b and 
RBV[48]. There are other reports, with conflicting or non-
reproducible results, so there is still controversy on their 
usefulness.
ZINC
It has been reported that zinc (Zn) supplementation 
down-regulated oxidative stress products such as 
malondialdehyde (MDA), 4-hydroxyalkenals, and 
8-hydroxydeoxyguanine in plasma; inhibited induction 
of tumor necrosis factor-α and interleukin-1β mRNA 
in mononuclear cells; and protected against NF-kB 
activation in mononuclear cells[49]. Polaprezinc (zinc plus 
l-carnosine), has been studied in many studies as an 
antioxidant adjuvant to IFN as treatment for chronic 
HCV infection, showing promising results[50]. There are 
several potential mechanisms supporting the antioxidant 
effects of zinc, such as the decrease of hepatic fibrosis, 
antioxidant activity, down-regulation of ferritin, and 
improvement in hepatic encephalopathy. Zn also is 
able to decrease HCV replication, then it has been used 
as an adjuvant for treatment of HCV infection, but 
further studies are needed to understand the involved 
mechanisms[51].
N-ACETYLCYSTEINE
On the other hand, Look et al[52] demonstrated that 
adjuvant antioxidant therapy with N-acetylcysteine/
HCV
End
opla
smic
retic
ulum
GSH
Nox4
O2
Nucleus
NS5A
E1/E
2
Core
ER stressCa 2+
Mit
och
ond
ria
O2-
NS4
B
↑ ROS
Core
H2O2
Nox1
Ask1
p38
P
JNK cJun
Akt
PI3K
P
P
JNK
P cJun
Oxidazed
Inactive
PTEN
GST
Trx OxidazedOxidazed
Figure 2  Cell signaling pathways modulated by increased reactive oxygen species levels in hepatitis C virus infected cells. ROS: Reactive oxygen species; 
HCV: Hepatitis C virus; GSH: Glutathione system; Trx: Thioredoxin; PI3K: Phosphoinositide-3 kinase.
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Selenium co-supplementation has not beneficial effect to 
improve antiviral activity in chronic hepatitis C patients 
upon a six-month interferon alpha monotherapy. These 
data suggest that antioxidant compounds could have a 
beneficial effect on necro-inflammatory variables, but 
have no effect on the viral cycle reduction.
GLYCYRRHIZIN
Another antioxidant evaluated in several clinical trials 
to combat HCV is glycyrrhizin, a free radical scavenger. 
Intravenous administration of glycyrrhizin, diminished 
transaminase enzyme levels, and decrease cellular 
damage in patients with chronic HCV infections[53,54]. In 
the Melhem et al[55] study, 50 HCV-infected patients were 
treated for 20 wk with a mix of seven oral antioxidants 
(glycyrrhizin, schisandra, silymarin, lipoic acid, ascorbic 
acid, L-glutathione, and alpha-tocopherol), along with 
four different intravenous preparations (glycyrrhizin, 
ascorbic acid, L-glutathione, B-complex) twice weekly 
for the first 10 wk. In patients who underwent this 
treatment, liver enzymes normalization occurred in 44% 
who had elevated ALT levels previous to treatment. 
Twenty five percent of the patients showed a decrease in 
viral load by one log or more. Histological improvement 
was also noted in 36.1% of patients. There were no 
major adverse reactions noticed[55]. These data portrays 
promising results for the use of glycyrrhizin in different 
liver diseases.
SILYMARIN COMPLEX
Silibinin is a major component of milk thistle (silymarin), 
which has been demonstrated in several in vitro and 
clinical trials that is a strong antioxidant and antifibrotic 
agent. The mechanisms of action of silymarin include 
different events, such as the stimulation of ribosomal 
RNA transcription and levels, protecting the cell mem-
brane from oxidative stress damage and blockage 
of the uptake of toxins. A combination of antioxidant 
compounds that have been shown to improve cellular 
and biochemical markers in chronic HCV patients is 
formed by alpha-lipoic acid, silymarin, and selenium[56,57]. 
There are conflicting results on the efficacy of silymarin. 
As an example a phase Ⅰ trial assessing the efficacy of 
oral doses of silymarin in non-responders HCV infected 
patients demonstrated no adverse effects but also 
showed no antiviral efficacy against HCV[41]. However, in 
other report the administration of intravenous (iv) silibilin 
in non-responders HCV infected patients decreased 
HCV-RNA levels in a dose-dependent manner[58]. It is 
reported that silibinin monotherapies of 5, 10, 15 or 
20 mg/kg for one week decrease viral load (from 0.55 
to 3.02 logs). The addition of combination of PEG-IFN/
RBV at day 8 resulted in a higher reduction of viremia, 
but some patients had slight rebound viremia upon iv 
silibinin treatment was discontinued despite continued 
standard of care. 
In another study, antiviral activity of silymarin com-
plex was evaluated in vitro by using the HCV-RNA 
polymerase and NS3/4A protease enzyme assays. 
Results demonstrated that silibinin A, silibinin B, their 
water-soluble dihydrogen succinate forms and Legalon 
SIL (a commercially available iv preparation of silibinin), 
were able to inhibit HCV-RNA polymerase activity (IC50 
of the order of 75-100 μmol/L). In addition, Silibinin 
A and silibinin B also decreased HCV genotype 1b 
replication and HCV genotype 2a strain JFH1 replication 
in cell culture. Interestingly, none of these agents 
affected the HCV protease function[59]. The antioxidant 
effects of silibinin have been showed in several cell 
studies. Silibinin is classified as an antioxidant compound 
because it blocks radical formation, binds many radical 
species (scavenger), interferes with lipid peroxidation 
mechanisms of membranes, and then increases the 
intracellular content of scavengers[60].
Gomez et al[61] in 2010 investigated the role of 
Viusid as an antioxidant and an immunomodulator in 
nonresponder HCV infected patients. Authors reported 
that MDA and 4-hydroxyalkenal levels were significantly 
decreased in serum of the treated patients when com-
pared with placebo.
GALLIC ACID
Gallic acid (GA) is a phenolic compound present in 
several natural sources and it has been reported to 
have various biological effects such as antioxidant, 
anti-inflammatory, antibiotic, anticancer, antiviral and 
cardiovascular protection. Recently, our group started 
to investigate whether GA is able to have an effect on 
HCV replication. Recently, we examined the effects of 
GA on HCV expression using a subgenomic HCV replicon 
cell culture system that expresses HCV-nonstructural 
proteins (unpublished data). We observed that GA down-
regulated NS5A-HCV protein expression (around 55%) 
and HCV-RNA levels (nearly 50%) in a time-dependent 
fashion compared with untreated cells. Interestingly, we 
observed that GA treatment decreased ROS levels at 
early times of exposure in cells expressing HCV proteins 
(manuscript in press). Similar results were found upon 
PDTC exposure. These findings suggest the possibility 
that antioxidant capacity of GA could contribute to the 
mechanism(s) involved in the down-regulation of HCV 
replication in hepatoma cells, however further experi-
ments are needed to confirm these findings.
HEME OXYGENASE REGULATION
There are some reports regarding to modulation of 
antioxidant enzymes as a HCV therapy, Zhu et al[62] 
worked with HO which catalyzes the rate-limiting 
reaction in the catabolism of heme which produces 
equimolar amounts of biliverdin, carbon monoxide and 
free iron. They reported that increased expression of 
HO-1 is associated with diminished HCV replication and 
also with an increase of the resistance of hepatocytes 
to oxidative damage. Based on this findings, heme 
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oxygenase regulation could be useful as an adjunctive 
antiviral therapy[62-64].
MITOQUINONE
Mitoquinone or MitQ (Antipodean Pharmaceuticals, 
Auckland, New Zeland) is a potent antioxidant that 
bonds the antioxidant moiety of coenzyme Q10 (known 
as ubiquinone) to a triphenylphosphonium cation. The 
cation causes the attached antioxidant to accumulate 
several-hundred fold within mitochondria in vivo upon 
oral administration, protecting them from oxidative 
injury and cell death. A phase-2 study of 28 d of MitQ 
revealed a decrease in serum aminotransferase in HCV 
treated patients[65,66].
QUERCETIN
Quercetin is a flavonoid antioxidant. In vitro treatment 
of HCV infected cells with quercetin diminished viral 
replication and infectious particle production. It has been 
shown that quercetin blocks viral protein production 
independently of viral genome replication; may help to 
elucidate the replication cycle and has potential use as 
antiviral agent helping to reduce virus production with 
low toxicity[67]. Additionally, dihydroquercetin has been 
shown to be beneficial as a hepatoprotective substance 
in the treatment of toxic hepatitis and liver fibrosis by 
enhancing antioxidant enzyme activity and decreasing 
the pro-oxidant effect[67,68].
S-ADENOSYLMETHIONINE
Further information into the hepatoprotective mecha-
nisms of antioxidant agents might be discovered by 
analyzing the relationship between glutathione precursor 
S-adenosylmethionine (SAM) and involved signaling 
pathways. Administration of SAM to non-responders 
patients infected with HCV, showed beneficial effects in 
combination with PEG-IFN and RBV. Feld et al[69] also 
suggest that this effect is through the methylation of 
STAT-1, a transcription factor responsible of interferon 
stimulated gene expression, which enhances its trans-
location to the nucleus. Our recent results indicate 
that there is a combination of actions regarding to 
the molecular mechanism of SAM on HCV replication. 
Administration of SAM to HCV replicon cells, leads to an 
increase of glutathione synthesis (unpublished data). 
There are also reports of SAM benefits in patients with 
alcoholic liver cirrhosis. The possible mechanisms of 
action of SAM include: (1) function as a methyl donor 
compound and restoring of mitochondrial glutathione 
levels, which is necessary to counterbalance the oxidant 
environment in cirrhotic liver; and (2) decreasing the 
hepatic production of nitric oxide (NO), through the 
modulation of iNOS enzyme. SAM perform these effects 
in part by accelerating synthesis of inhibitor of kB-
alpha and regulating the activation of NF-kB, thereby 
decreasing the transactivation of iNOS promoter[70]. 
Nevertheless, further experiments are needed to explore 
the participation of NO synthase-2 promoter and the 
effect of SAM in HCV replication. 
We are currently investigating the molecular mechan-
isms of SAM against HCV in a subgenomic replicon 
cell model. We found that SAM is capable of modulate 
the antioxidant defense systems at transcriptional and 
translational level (SOD1, SOD2 and thioredoxin 1); we 
also found that biosynthesis of GSH in presence of SAM 
is increased in short periods of time (2-6 h). In addition, 
MAT1/MAT2 turnover is switched in presence of SAM 
(unpublished data). MAT1 is the enzyme responsible of 
the conversion of methionine to s-adenosylmethionine, 
and it is down-regulated in hepatocarcinoma and liver 
diseases. Presently, we need more experimental data to 
understand the role of SAM in the modulation of HCV.
ACETYLSALICYLIC ACID
Several studies including our reported findings demon-
strated that sodium salicylate and acetylsalicylic acid 
(ASA) block the replication of flaviviruses, such as 
Japanese encephalitis virus, HCV and dengue virus[71,72]. 
Liao et al[71] demonstrated that salicylates inhibit 
flavivirus infection through a mechanism including p38-
MAPK activity, but not NF-kB activation. In other hand, 
Mazur et al[72] reported inhibition of influenza virus 
replication in vitro and in vivo by ASA. This antiviral 
activity was mediated by a mechanism including 
expression of proapoptotic factors, decrease of caspase 
activation, and blocking of the nuclear export of viral 
ribonucleoproteins[72]. In 2008, our research group 
demonstrated that ASA presented anti-HCV proper-
ties in HCV-replicon cells through inhibition of COX-2 
activity and expression, which is mediated in part by 
the activation of (MEK1/2)/p38 MAPKs[73,74]. Our results 
suggest that ASA in combination with standard therapy 
could be an excellent adjuvant in the treatment of 
chronic HCV infection.
As antiviral agents, antioxidants could be used in four 
different ways: (1) to deteriorate cellular mechanisms 
involved in HCV replication; (2) to improve liver enzyme 
activity and levels; (3) to counteract and protect against 
liver cell injury; and (4) to improve interferon anti-viral 
response. Triple antioxidants therapies have been tested 
in clinical trials, which include alpha-lipoic acid, silymarin 
and selenium in order to suppress HCV-induced liver 
damage, when used together with Vitamins C and E, 
and in a healthy diet and exercise regime[43,75,76]. 
Several studies are in favor of a positive control 
of HCV replication by oxidative stress and to search 
counteracting this effect. Taking all these data together, 
there is plenty of evidence suggesting that antioxidants 
can effectively improve the response of HCV infected 
patients, even if they are non-responders. There are 
also proofs that antioxidants ameliorate the oxidative 
and nitrosative stress in liver disease, ultimately de-
creasing inflammation and fibrosis progression. Some 
investigators think that although it is important testing 
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these antioxidant compounds in clinical trials, they make 
emphasis on the need of researching the side effects of 
different antioxidants on HCV replication before its use 
as therapy. However, there are conflicting data published 
by Nakamura et al[77], where they reported an enhanced 
HCV replication with resveratrol treatment, so further 
research is needed.
CONCLUSION
It is well established that HCV infection leads to strong 
cellular oxidative stress, triggering several HCV-
associated metabolic disorders including HCC, steatosis, 
liver fibrosis, cirrhosis and iron overload. Today, several 
molecular interplays and signaling pathways involving 
viral proteins, host cell factors, ROS-generating enzymes 
and cellular antioxidant systems have been elucidated. 
In fact, several intracellular signaling pathways are 
altered by the expression of HCV proteins in favor of 
virus replication and they are finely regulated by the 
cellular redox state. Additional mechanisms by which 
HCV induces and modulate oxidative stress still remain 
to be discovered and require further studies. With the 
current findings regarding the dual function of the 
oxidative stress induced by the virus and the host cell, 
it may be possible to establish new and more effective 
therapeutic targets for HCV treatment.
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